同源康医药-B在研1类新药甲磺酸艾多替尼片被国家药品监督管理局药品审评中心纳入优先审评品种名单

Group 1 - The core point of the article is that the company, 同源康医药-B (02410), has had its investigational drug, Tyrosine Kinase Inhibitor (TY-9591), included in the priority review list by the National Medical Products Administration (NMPA) [1] - The drug is intended for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletions (19DEL) or exon 21 (L858R) substitution mutations, along with CNS metastases [1]